Novel vaccines against hpv and hpv-related diseases

A fusion protein comprising an anti-CD40 antibody or fragment thereof, comprising at least three complementarity determining regions (CDRs) from each of a heavy and light chain of an anti-CD40 antibody, at least one peptide linker and at least one human papillomavirus (HPV) E6 antigen and at least one HPV E7 antigen, wherein the E6 and E7 antigens comprise:

• (i) an antigen with at least 90% sequence identity to SEQ ID NO:1 and an antigen with at least 90% sequence identity to SEQ ID NO:2;
• or
• (ii) an antigen with at least 90% sequence identity to SEQ ID NO:3 and an antigen with at least 90% sequence identity to SEQ ID NO:4.

17-21. (canceled)

23-24. (canceled)

(canceled)

-31. (canceled)

-55. (canceled)

-83. (canceled)

88-89. (canceled)

-134. (canceled)

A method for inducing an immune response to at least one HPV epitope comprising administering to a patient a composition comprising a fusion protein, wherein the fusion protein comprises an anti-CD40 antibody having a heavy chain and a light chain, wherein:

• the light chain has an amino acid sequence with at least 95% sequence identity to SEQ ID NO:7 and comprises a variable region having a CDR1, CDR2, and CDR3 with the amino acid sequences of SEQ ID Nos:11-13, respectively;
• and
• the heavy chain has an amino acid sequence with at least 95% sequence identity to SEQ ID NO:19 and comprises a variable region having a CDR1, CDR2, and CDR3 with the amino acid sequences of SEQ ID Nos:14-16, respectively.